IDH1 and central nervous system cancer: The high-frequency IDH1/2 mutations in glioma have paradoxical implications to glioma diagnosis, management, and therapy: the IDH1/2 mutation promotes malignant transformation of primary glioma, while it provides a potential anti-tumor advantage.